Skip to main content
Fredun Pharmaceuticals Limited logo

Fredun Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 539730 ISIN · INE194R01017 LEI · 984500A2DC584976AC60 BSE.NS Manufacturing
Open in API
Filings indexed 527 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country IN India
Listing BSE.NS 539730

About Fredun Pharmaceuticals Limited

http://www.fredungroup.com/

Fredun Pharmaceuticals Limited specializes in the development, manufacturing, and marketing of a broad range of healthcare formulations. The product portfolio includes diverse dosage forms such as tablets, capsules, ointments, and liquid orals, covering therapeutic areas including cardiology, diabetology, anti-infectives, and gastroenterology. The company also operates specialized divisions for nutraceuticals and veterinary products. With a focus on quality and affordability, the organization maintains manufacturing facilities compliant with WHO-GMP standards. Its operations extend across various international markets, supported by a robust export strategy and a commitment to meeting global regulatory requirements. The company emphasizes research-driven production to address evolving medical needs through a comprehensive suite of healthcare solutions.

Recent filings

Filing Released Lang Actions
Fredun Pharmaceuticals Limited Unveils Cellular Longetivity Dedicated Platform Daulcel
Regulatory Filings Classification · 90% confidence The document is a press release announcing a new product platform (‘Daulcél’) sent to the stock exchange. It contains no financial statements, vote results, managerial changes, or other report content. It is a general corporate announcement that does not fit any specialized category, making Regulatory Filings (RNS) the appropriate classification.
2026-05-15 English
Fredun Pharmaceuticals Limited announces Strategic Launch of Hormone Range Products.
Regulatory Filings Classification · 78% confidence The document is a press release filed with the BSE listing department announcing a new product launch (HORMONE RANGE PRODUCTS). It contains no financial statements, management changes, share transactions, dividends, or regulatory/legal specifics beyond a standard corporate announcement. It serves as a general regulatory announcement to the exchange rather than an in-depth report. Therefore it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-15 English
Monitoring Agency report for the quarter ended 31st March 2026.
Capital/Financing Update Classification · 85% confidence The document is a compliance disclosure under SEBI (LODR) Regulation 32, providing a Statement of Deviation or Variation in the utilisation of proceeds raised through a preferential issue. It is not an annual or interim financial report, nor a transcript or AGM material. Instead, it updates stakeholders on financing activity—specifically, monitoring the use of funds from an equity issuance. This aligns with the “Capital/Financing Update” category, which covers updates on fundraising and capital structure changes.
2026-05-15 English
The Board of Directors of the Company at their Board Meeting held on Friday, May 15, 2026 at 07:30 P.M through Video Conferencing (VC) inter alia transacted the following businesses: 1. ....
Regulatory Filings Classification · 82% confidence The document is an official exchange filing under SEBI LODR Regulation 30, providing the outcome of a Board meeting (i.e., a regulatory announcement to the stock exchange). It contains no financial statements or appointment changes and is not the report itself but an announcement of proceedings. This fits the fallback “Regulatory Filings” category.
2026-05-15 English
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve 1. Consider and approve ....
Regulatory Filings Classification · 75% confidence The document is a prior intimation under SEBI LODR Regulation 29/33 notifying a board meeting date to consider and approve audited results, dividend and bonus share recommendations. It contains no actual financial statements or product presentations, nor is it a call transcript, proxy, or dividend declaration, and does not announce a change in management. It is essentially a regulatory notice to the exchange. Therefore it falls into the general regulatory filings category (RNS).
2026-05-15 English
Please find enclosed press release titled "Fredun Pharmaceuticals Expands Manufacturing Base with Fifty Facility at Palghar" issued by Fredun Pharmaceuticals Limited.
Regulatory Filings
2026-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.